HighTower Advisors
FTH

HighTower Advisors’s Faeth Therapeutics FTH Stock Holding History

HighTower Advisors’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,511
Closed -$78K – 3501
2022
Q3 		$78K Hold
2,511
– – ﹤0.01% 2816
2022
Q2 		$114K Hold
2,511
– – ﹤0.01% 2766
2022
Q1 		$116K Buy
+2,511
New +$200K ﹤0.01% 2963

Other funds holding FTH

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors's FTH Position: Q4 2022 in Review

HighTower Advisors sold out of Faeth Therapeutics (FTH) in Q4 2022, closing a stake of 2,511 shares — an estimated $78K sold.

HighTower Advisors first reported a position in FTH in Q1 2022 and held it in 3 quarters. The position peaked at $116K in Q1 2022. 26 funds tracked by Wall St. Rank hold FTH as of Q4 2022.

  • HighTower Advisors reported no remaining Faeth Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HighTower Advisors sold 2,511 Faeth Therapeutics shares in Q4 2022, an estimated $78K.
  • HighTower Advisors first reported a position in Faeth Therapeutics in Q1 2022 and held it in 3 quarters.
  • HighTower Advisors's Faeth Therapeutics position peaked at $116K in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.